drugset

drugset / Trial / NCT01481233

Oral Colchicine in Men With Castrate Resistant Prostate Cancer

NCT01481233 ↗

Phase 2 Withdrawn Milton S. Hershey Medical Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the prostate specific antigen response to continuous low dose oral colchicine.

Timeline

Start: 2013-05
Primary completion: 2013-08
Completion: 2013-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Colchicine	Small molecule	0.6 mg	Oral

Indications